Non-obstructive azoospermia Cell Models for Research

Non-obstructive azoospermia (NOA) is the most severe form of male infertility, affecting approximately 1% of the male population and 10-15% of infertile men (WHO, 2023). It is characterized by the absence of sperm in the ejaculate due to impaired spermatogenesis, not a physical obstruction. The condition is a major contributor to male factor infertility, which accounts for about 50% of infertility cases globally. NOA is associated with various etiologies, including genetic abnormalities (e.g., Klinefelter syndrome, Y-chromosome microdeletions), hormonal imbalances, and environmental factors. The psychological and economic burden is substantial, with many couples seeking assisted reproductive technologies (ART) such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI), though success rates are limited. Research into the molecular mechanisms of NOA is critical for developing novel therapeutic strategies and improving reproductive outcomes.

NOA is an ideal model for studying spermatogenesis and male infertility due to its well-defined clinical phenotype and the availability of testicular biopsies for molecular analysis. The disease encompasses a spectrum of histopathological patterns, including Sertoli cell-only syndrome, maturation arrest, and hypospermatogenesis, each with distinct molecular signatures. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas, provide gene expression profiles of normal and pathological testicular tissues. Open questions include the identification of key genetic drivers, the role of somatic cell dysfunction (e.g., Sertoli cells), and the development of in vitro models to recapitulate spermatogenesis. Gene-edited cell models, such as CRISPR knockout and knock-in lines, offer a powerful approach to functionally validate candidate genes and dissect molecular pathways, thereby accelerating translational research.

While NOA is not a cancer, it shares common molecular pathways with testicular cancer, particularly germ cell tumors. Key pathways involved in spermatogenesis and disrupted in NOA include:

• • PI3K/AKT signaling: Regulates germ cell survival and proliferation. Dysregulation leads to apoptosis and impaired spermatogenesis.
• • MAPK/ERK pathway: Essential for meiotic progression and spermatid differentiation. Aberrant activation is linked to maturation arrest.
• • TGF-β/BMP signaling: Controls Sertoli cell function and germ cell niche. Mutations in ligands or receptors disrupt spermatogenesis.
• • Wnt/β-catenin pathway: Involved in spermatogonial stem cell self-renewal and differentiation. Altered signaling contributes to germ cell depletion.

These pathways are interconnected and often converge on transcription factors such as DAZL, BOLL, and STRA8, which are critical for germ cell development.

Data compiled from COSMIC and ClinVar, with frequencies based on NOA cohorts. These alterations highlight the genetic heterogeneity of NOA and provide targets for gene editing.

The molecular networks deregulated in NOA include:

• • Sertoli cell-germ cell communication: Disrupted by mutations in genes such as GDNF, FGF2, and BMP4, leading to impaired niche function.
• • Apoptosis pathways: Overexpression of pro-apoptotic factors (BAX, BAD) and downregulation of anti-apoptotic factors (BCL2) cause germ cell loss.
• • Epigenetic regulators: DNA methyltransferases (DNMT3A, DNMT3B) and histone modifiers (HDACs) are altered, affecting gene expression patterns.
• • RNA-binding proteins: DAZL, BOLL, and PUM1 regulate mRNA stability and translation, critical for post-meiotic differentiation.

These networks are potential targets for therapeutic intervention and can be studied using gene-edited cell models.

Organoids derived from testicular tissue have been developed to recapitulate spermatogenesis in vitro. They retain the cellular complexity and can be used for drug testing and mechanistic studies. However, their limited availability and reproducibility remain challenges.

Animal models for NOA include:

• • Genetically engineered mouse models (GEMMs): Knockout mice for DAZL, SYCP3, and TEX11 exhibit azoospermia phenotypes, providing valuable in vivo systems.
• • Chemically induced models: Administration of busulfan or doxorubicin depletes germ cells, mimicking NOA.
• • Surgical models: Vasectomy or efferent duct ligation can induce obstructive azoospermia, but not NOA.
• • Patient-derived xenografts (PDX): Testicular tissue from NOA patients can be xenografted into immunodeficient mice to study spermatogenesis, though limited by tissue availability.

These models are essential for validating gene function and testing therapeutic approaches.

CRISPR-based gene editing has enabled the creation of isogenic cell lines with specific genetic modifications, providing powerful tools for NOA research. Examples include:

• • DAZL knockout Sertoli cell lines: These lines lack DAZL expression, allowing investigation of its role in germ cell support.
• • SYCP3 knock-in lines: Introduction of disease-associated mutations into spermatocyte cell lines to study meiotic defects.
• • TEX11 knockout lines: Used to examine the impact on meiotic recombination and DNA repair.

These gene-edited models are commercially available from various sources, ensuring sequence verification and quality. They enable functional studies, drug screening, and target validation, accelerating the development of therapies for NOA.

Gene-edited cell lines are instrumental in functional genomics to validate candidate genes identified in patient cohorts. For example, knocking out DAZL in Sertoli cells can reveal its role in regulating germ cell survival and differentiation. Similarly, introducing a SYCP3 mutation into a spermatocyte cell line can confirm its effect on meiotic progression. These models allow researchers to study gene function in a controlled environment, complementing animal studies.

Isogenic cell line pairs (wild-type vs. gene-edited) are used in high-throughput drug screening to identify compounds that rescue or exacerbate the phenotype. For instance, a DAZL knockout Sertoli cell line can be used to screen for drugs that enhance germ cell support. Additionally, resistance mechanisms can be studied by exposing cells to chemotherapeutic agents and selecting for resistant clones, then analyzing genetic changes.

CRISPR-based synthetic lethality screens can identify genes that are essential for survival in NOA-specific genetic backgrounds. For example, in cells with a TEX11 knockout, screening for genes whose depletion causes cell death can reveal potential therapeutic targets. This approach can also identify biomarkers for diagnosis or prognosis by correlating gene expression with clinical outcomes.